QUOTED. 20 September 2019. Eran Atlas.
Tel-Aviv, Isreal-based DreaMed Diabetes received another US Food and Drug Administration clearance for its AI-powered Advisor Pro software, which helps providers manage and optimize treatment for patients with type 1 diabetes. See what DreaMed's CEO, Eran Atlas, said about it here.
"What we have right now with our technology is the ability to provide recommendations for the entire insulin pump type 1 population, so we are more than doubling the market potential for our business." – Eran Atlas, CEO, DreaMed Diabetes
Click here for a free trial of Medtech Insight